Similar strategies of combining PD-1 antagonists with a therapeutic vaccine have been used experimentally in cancer therapy to positive effect and are being explored clinically (Massarelli et al., 2019; Verma et al., 2019; Kaumaya et al., 2020; Ott et al., 2020; Peng et al., 2021). Here, PDCD1 is linked to cancer.